| DIRECT COMPETITOR COMPARISON | |
| GTCB | BAX | Pvt1 | TLCR | Industry | | Market Cap: | 24.74M | 33.05B | N/A | 2.31B | 100.26M | | Employees: | 153 | 48,500 | N/A | 4,650 | 68 | | Qtrly Rev Growth (yoy): | -74.40% | -0.20% | N/A | 12.90% | 19.70% | | Revenue (ttm): | 2.64M | 12.22B | N/A | 1.54B | 14.01M | | Gross Margin (ttm): | 33.01% | 51.23% | N/A | 40.48% | 65.67% | | EBITDA (ttm): | -32.52M | 3.37B | N/A | 314.03M | -12.30M | | Oper Margins (ttm): | -1,317.62% | 22.54% | N/A | 18.66% | -149.46% | | Net Income (ttm): | -32.33M | 2.20B | N/A | 163.25M | N/A | | EPS (ttm): | -3.107 | 3.562 | N/A | 1.890 | -0.33 | | P/E (ttm): | N/A | 15.39 | N/A | 10.21 | 16.37 | | PEG (5 yr expected): | N/A | 1.25 | N/A | 0.95 | 1.31 | | P/S (ttm): | 9.35 | 2.70 | N/A | 1.50 | 9.35 |
|
| BAX = Baxter International Inc. | | Pvt1 = CSL Behring (privately held) | | TLCR = Talecris Biotherapeutics Holdings Corp. | | Industry = Biotechnology | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.50 | 0.00% | 57.19B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.92 | 0.00% | 13.57B | 15.70 | | Genzyme Corp. | GENZ | 51.07 | 0.00% | 13.55B | 29.12 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.56 | 0.00% | 41.90B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.95 | 0.00% | 8.91B | 1019.39 | | Teva Pharmaceutical Industries Limited | TEVA | 52.88 | 0.00% | 46.59B | 48.38 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 36.96 | 0.00% | 3.92B | 19.05 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.95 | 0.00% | 2.97B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.01 | 0.00% | 5.50B | 110.49 | | Pfizer Inc. | PFE | 18.25 | 0.00% | 147.27B | 15.16 | | Johnson & Johnson | JNJ | 62.89 | 0.00% | 173.52B | 13.73 | | GlaxoSmithKline plc | GSK | 42.26 | 0.00% | 107.13B | 13.42 | | Sanofi-Aventis | SNY | 38.43 | 0.00% | 100.35B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.38 | 0.00% | 125.78B | 16.58 | | RHHBY.PK | 41.46 | 0.00% | N/A | N/A | | AstraZeneca plc | AZN | 45.29 | 0.00% | 65.67B | 9.09 | | Abbott Laboratories | ABT | 54.08 | 0.00% | 83.65B | 14.65 | | Bristol-Myers Squibb Co. | BMY | 25.38 | 0.00% | 50.28B | 13.13 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | BAX | | 8 HealthCare Stocks With 3%+ Dividends
Sun 12:52am -
at Seeking Alpha | | • | BAX | | 10 Dividend Picks For Your Portfolio: Chief Investors
Wed, Nov 25 -
at CNBC | | • | BAX | | [video] The Dividend Strategy
Wed, Nov 25 -
at CNBC | | • | BAX | | Becton Acquires HandyLab
Mon, Nov 23 -
Zacks.com | | • | BAX | | 30 High Yielding Option Write Ideas for November Option Expiration Friday
Fri, Nov 20 -
at Seeking Alpha | | • | BAX | | Healthcare Spin Off Companies Offer Opportunity To Investors According To Credit Suisse Senior Analyst
Thu, Nov 19 -
Wall Street Transcript | | • | BAX | | Sector Snap: UBS upbeat on medical tech stocks
Wed, Nov 18 -
AP | | • | TLCR | | Biotech Stocks Hot Right Now, Ho-Hum in the Long Run
Wed, Nov 18 -
at The Wall Street Journal Online | | • | BAX | | Coverage initiated on Baxter by Morgan Keegan
Wed, Nov 18 -
Briefing.com | | • | TLCR | | Talecris to invest $268.7 million in NC plant
Fri, Nov 13 -
AP | | • | TLCR | | Talecris to Invest $268.7 Million to Expand its Manufacturing Facility in Clayton
Fri, Nov 13 -
Business Wire | | • | TLCR | | There Will Be Blood (Plasma)
Wed, Nov 11 -
at Motley Fool | | • | TLCR | | Coverage initiated on Talecris Biotherapeutics by Barclays Capital and Citigroup
Wed, Nov 11 -
Briefing.com | | | All Headlines for these symbols... |
|
|
|
1.48% Nasdaq 0.00%
Competitors
